Bausch + Lomb Corporation (BLCO) key performance indicators and operating metrics (78 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Pharmaceuticals revenue | 354M | FY2026-Q2 |
| Surgical revenue | 256M | FY2026-Q2 |
| Vision Care revenue | 784M | FY2026-Q2 |
| Adjusted earnings per share attributable to Bausch + Lomb Corporation | 0.15 USD_per_share | FY2026-Q2 |
| Adjusted earnings before interest, taxes, depreciation, and amortization | 241M | FY2026-Q2 |
| Contact lens revenue | 270M | FY2026-Q2 |
| Brandedand Other Generic Products revenue | 68M | FY2026-Q2 |
| Brandedand Other Generic Products · Vision Care revenue | 13M | FY2026-Q2 |
| Device Products revenue | 524M | FY2026-Q2 |
| Device Products · Surgical revenue | 254M | FY2026-Q2 |
| Ophthalmic Pharmaceuticals · Pharmaceutical Products revenue | 299M | FY2026-Q2 |
| Other Revenues revenue | 5M | FY2026-Q2 |
| Other Revenues · Surgical revenue | 2M | FY2026-Q2 |
| Other Revenues · Vision Care revenue | 3M | FY2026-Q2 |
Back to BLCO overview · BLCO earnings · BLCO holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.